Clinical Research Directory
Browse clinical research sites, groups, and studies.
Minocycline for Chronic Autoimmune Uveitis
Sponsor: Sun Yat-sen University
Summary
Autoimmune uveitis is one kind of non-infectious, sight-threatening, relapsing and severe ocular disease. Approximately 20%-25% autoimmune uveitis patients suffer from the dilemma of blindness for the chronic and persistent inflammatory state in the eyes, which results in continuous destroy in the structure of the eyes and gradually leads to irreversible damage on visual function. However, it shows limiting efficacy of current treatment including glucocorticoids, immunosuppressant and biologics for chronic autoimmune uveitis. Minocycline has been regarded to have anti-apoptosis and immunemodulatory function for decades and it has been illustrated to be beneficial in several neuro-degenerative and neuro-inflammatory diseases. This trial aims to investigate the efficacy and safety of minocycline for chronic autoimmune uveitis with retinal degenerative changes.
Official title: The Efficacy and Safety of Minocycline for Chronic Autoimmune Uveitis
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2021-12-01
Completion Date
2026-12-31
Last Updated
2023-04-18
Healthy Volunteers
No
Conditions
Interventions
minocycline
minocycline capsule 100mg per day orally
Locations (1)
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China